700 related articles for article (PubMed ID: 34696334)
1. The Cross-Talk between Thrombosis and Inflammatory Storm in Acute and Long-COVID-19: Therapeutic Targets and Clinical Cases.
Acanfora D; Acanfora C; Ciccone MM; Scicchitano P; Bortone AS; Uguccioni M; Casucci G
Viruses; 2021 Sep; 13(10):. PubMed ID: 34696334
[TBL] [Abstract][Full Text] [Related]
2. Coagulopathy of hospitalised COVID-19: A Pragmatic Randomised Controlled Trial of Therapeutic Anticoagulation versus Standard Care as a Rapid Response to the COVID-19 Pandemic (RAPID COVID COAG - RAPID Trial): A structured summary of a study protocol for a randomised controlled trial.
Sholzberg M; Tang GH; Negri E; Rahhal H; Kreuziger LB; Pompilio CE; James P; Fralick M; AlHamzah M; Alomran F; Tseng E; Lim G; Lillicrap D; Carrier M; Áinle FN; Beckett A; da Costa BR; Thorpe K; Middeldorp S; Lee A; Cushman M; Jüni P
Trials; 2021 Mar; 22(1):202. PubMed ID: 33691765
[TBL] [Abstract][Full Text] [Related]
3. Cytokine storm associated coagulation complications in COVID-19 patients: Pathogenesis and Management.
Savla SR; Prabhavalkar KS; Bhatt LK
Expert Rev Anti Infect Ther; 2021 Nov; 19(11):1397-1413. PubMed ID: 33832398
[TBL] [Abstract][Full Text] [Related]
4. Thrombocytopathy and endotheliopathy: crucial contributors to COVID-19 thromboinflammation.
Gu SX; Tyagi T; Jain K; Gu VW; Lee SH; Hwa JM; Kwan JM; Krause DS; Lee AI; Halene S; Martin KA; Chun HJ; Hwa J
Nat Rev Cardiol; 2021 Mar; 18(3):194-209. PubMed ID: 33214651
[TBL] [Abstract][Full Text] [Related]
5. Coagulopathy, thromboembolic complications, and the use of heparin in COVID-19 pneumonia.
Costanzo L; Palumbo FP; Ardita G; Antignani PL; Arosio E; Failla G;
J Vasc Surg Venous Lymphat Disord; 2020 Sep; 8(5):711-716. PubMed ID: 32561465
[TBL] [Abstract][Full Text] [Related]
6. Enoxaparin for primary thromboprophylaxis in ambulatory patients with coronavirus disease-2019 (the OVID study): a structured summary of a study protocol for a randomized controlled trial.
Barco S; Bingisser R; Colucci G; Frenk A; Gerber B; Held U; Mach F; Mazzolai L; Righini M; Rosemann T; Sebastian T; Spescha R; Stortecky S; Windecker S; Kucher N
Trials; 2020 Sep; 21(1):770. PubMed ID: 32907635
[TBL] [Abstract][Full Text] [Related]
7. Anticoagulation for COVID-19 Patients: A Bird's-Eye View.
Kreidieh F; Temraz S
Clin Appl Thromb Hemost; 2021; 27():10760296211039288. PubMed ID: 34595937
[TBL] [Abstract][Full Text] [Related]
8. Risk Benefit Analysis in Reference to use of LMWH in COVID-19.
Samajdar SS; Sam PA; Moitra S; Ray Y; Pal J; Joshi SR; Tripathi SK
J Assoc Physicians India; 2020 Sep; 68(9):52-61. PubMed ID: 32798346
[TBL] [Abstract][Full Text] [Related]
9. Venous thrombosis epidemiology, pathophysiology, and anticoagulant therapies and trials in severe acute respiratory syndrome coronavirus 2 infection.
Obi AT; Barnes GD; Napolitano LM; Henke PK; Wakefield TW
J Vasc Surg Venous Lymphat Disord; 2021 Jan; 9(1):23-35. PubMed ID: 32916371
[TBL] [Abstract][Full Text] [Related]
10. Role of current and emerging antithrombotics in thrombosis and cancer.
Mousa SA
Drugs Today (Barc); 2006 May; 42(5):331-50. PubMed ID: 16801996
[TBL] [Abstract][Full Text] [Related]
11. Viral Coagulopathy in Patients With COVID-19: Treatment and Care.
Kipshidze N; Dangas G; White CJ; Kipshidze N; Siddiqui F; Lattimer CR; Carter CA; Fareed J
Clin Appl Thromb Hemost; 2020; 26():1076029620936776. PubMed ID: 32687449
[TBL] [Abstract][Full Text] [Related]
12. COVID-19-associated coagulopathy and antithrombotic agents-lessons after 1 year.
Leentjens J; van Haaps TF; Wessels PF; Schutgens REG; Middeldorp S
Lancet Haematol; 2021 Jul; 8(7):e524-e533. PubMed ID: 33930350
[TBL] [Abstract][Full Text] [Related]
13. Heparin dosage, level, and resistance in SARS-CoV2 infected patients in intensive care unit.
Novelli C; Borotto E; Beverina I; Punzi V; Radrizzani D; Brando B
Int J Lab Hematol; 2021 Dec; 43(6):1284-1290. PubMed ID: 33855802
[TBL] [Abstract][Full Text] [Related]
14. Coagulopathies in novel coronavirus (SARS-CoV-2) pandemic: Emerging evidence for hematologists.
Al-Subaie AM
Saudi J Biol Sci; 2021 Jan; 28(1):956-961. PubMed ID: 33169062
[TBL] [Abstract][Full Text] [Related]
15. COVID-19-associated coagulopathy and disseminated intravascular coagulation.
Asakura H; Ogawa H
Int J Hematol; 2021 Jan; 113(1):45-57. PubMed ID: 33161508
[TBL] [Abstract][Full Text] [Related]
16. Coagulopathy, Venous Thromboembolism, and Anticoagulation in Patients with COVID-19.
Dobesh PP; Trujillo TC
Pharmacotherapy; 2020 Nov; 40(11):1130-1151. PubMed ID: 33006163
[TBL] [Abstract][Full Text] [Related]
17. Diagnosis and treatment of disseminated intravascular coagulation in COVID-19 patients: a scoping review.
Mori H; Ohkawara H; Togawa R; Rikimaru M; Shibata Y; Ikezoe T
Int J Hematol; 2021 Mar; 113(3):320-329. PubMed ID: 33550533
[TBL] [Abstract][Full Text] [Related]
18. Interrelationship between COVID-19 and Coagulopathy: Pathophysiological and Clinical Evidence.
Ragnoli B; Da Re B; Galantino A; Kette S; Salotti A; Malerba M
Int J Mol Sci; 2023 May; 24(10):. PubMed ID: 37240292
[TBL] [Abstract][Full Text] [Related]
19. Do inflammaging and coagul-aging play a role as conditions contributing to the co-occurrence of the severe hyper-inflammatory state and deadly coagulopathy during COVID-19 in older people?
Xu K; Wei Y; Giunta S; Zhou M; Xia S
Exp Gerontol; 2021 Aug; 151():111423. PubMed ID: 34048906
[TBL] [Abstract][Full Text] [Related]
20. Protease-activated receptor 1 as a potential therapeutic target for COVID-19.
Rovai ES; Alves T; Holzhausen M
Exp Biol Med (Maywood); 2021 Mar; 246(6):688-694. PubMed ID: 33302737
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
